Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-03-17 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin, identified by the 'Informazione Regolamentata' header and the date/time stamp typical of regulatory dissemination systems (Euronext Milan). The subject ('Oggetto') explicitly states that the company received U.S. FDA 510(K) clearance for a new diagnostic assay. This type of announcement, detailing a significant regulatory or operational milestone that is not a standard periodic financial report (like 10-K or IR), falls best under the general category of Regulatory Filings (RNS) or potentially a specific operational update. Since there is no specific category for FDA clearance announcements, and it is a formal, non-financial regulatory update, RNS is the most appropriate fallback. The document is short and announces an event rather than being the full report itself, ruling out classifications like AR or ER.
2023-03-17 English
DiaSorin riceve l'autorizzazione 510k per il test COVID Flu
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement from DiaSorin, dated March 17, 2023, regarding receiving 510(k) authorization from the US FDA for a new molecular test (SIMPLEXA™ COVID-19 & FLU A/B DIRECT). The structure includes metadata typical of regulatory disclosures (Informazione Regolamentata, Data/Ora Ricezione) and the content focuses on a specific business/product development event (FDA approval). This type of announcement, detailing a significant operational or regulatory milestone that impacts the company's offering, fits best under the general category of Regulatory Filings (RNS) or potentially Capital/Financing Update (CAP) if it were about fundraising, but here it is about product clearance. Since it is a specific regulatory event announcement that doesn't fit perfectly into ER, IR, or M&A, RNS (Regulatory Filings) is the most appropriate general category for non-standard, material announcements, although it is a specific business update. Given the options, and that it is a material announcement of regulatory success, RNS serves as the best fit for a general regulatory disclosure that isn't a standard periodic report or a specific transaction notice. It is not a full report (10-K, IR), nor a management change (MANG), nor a dividend notice (DIV). It is a material regulatory event announcement.
2023-03-17 Italian
DiaSorin S.p.A. - Update 2023 Annual Calendar of Corporate Events
Report Publication Announcement Classification · 99% confidence The document is titled 'DiaSorin S.p.A. - Update 2023 Annual Calendar of Corporate Events'. It explicitly lists scheduled dates for key corporate activities throughout 2023, including Board of Directors meetings for approving financial statements (March 27, May 12, July 27, November 10) and the date for the Annual General Meeting (April 28). Since the document's primary purpose is to announce the schedule of future corporate events, including the AGM and financial report approvals, it functions as a general corporate update regarding future disclosures and meetings. Given the options, this is best classified as a general regulatory announcement or update that doesn't fit the specific definitions of an ER, 10-K, or IR. However, since it specifically mentions the date for the Annual General Meeting (AGM) and the approval of statutory/consolidated financial statements, it is closely related to future reporting events. Because it is an announcement *about* future events rather than the event itself or the report itself, and it is a formal regulatory filing (Informazione Regolamentata), the most appropriate classification among the specific options is either RPA (Report Publication Announcement) or RNS (Regulatory Filings - fallback). Since it announces the calendar for multiple events, including the AGM, and is a formal regulatory notice, RNS is a strong candidate, but RPA specifically covers announcements regarding the timing/publication of reports. Given the content is a calendar update, RNS (Regulatory Filings) serves as the best general fit for this type of forward-looking corporate schedule disclosure that isn't a specific report or a direct AGM/DEF 14A filing.
2023-02-07 Italian
Comunicato Internal Dealing
Director's Dealing Classification · 100% confidence The document header explicitly states 'Oggetto: Comunicato Internal Dealing' (Subject: Internal Dealing Communication). Furthermore, the template used is titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The document is a formal notification, not a short announcement linking to a report, so the RPA/RNS fallback is not appropriate. The classification must be DIRS.
2022-12-22 Italian
Report on the treasury shares buy-back plan of DiaSorin S.p.A. - Period 02/12/2022- 07/12/2022
Transaction in Own Shares Classification · 100% confidence The document is a regulatory filing from DiaSorin S.p.A. dated December 7, 2022, reporting on the weekly activity of its treasury shares buy-back plan for the period 02/12/2022 - 07/12/2022. The core subject is the purchase of own shares (treasury shares) and the resulting holding percentage. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers company buy-backs or sales of its own shares. Although it is a report, it is not a comprehensive annual (10-K) or interim (IR) report, nor is it a general announcement of a report (RPA). It is a specific disclosure about share transactions.
2022-12-07 English
Informativa sul programma di acquisto di azioni proprie di DiaSorin S.p.A. - Periodo 2/12/2022 - 7/12/2022
Transaction in Own Shares Classification · 98% confidence The document is titled 'INFORMATIVA SETTIMANALE SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE DI DIASORIN S.P.A.' (Weekly Information on the Share Buyback Program of DiaSorin S.p.A.). It details the number of own shares purchased during a specific period (2/12/2022 - 7/12/2022) and provides a detailed transaction log in tables. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). Although it is a report, the primary action described is the repurchase of shares, making POS the most specific classification over a general RPA or RNS.
2022-12-07 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.